In most countries, prostate cancer incidence and mortality rates decreased or were stable in the most recent five-year period ...

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. This may include ...

The immunotherapy, CAN-2409, in combination with radiation therapy, helped 75.2% patients live without any sign of the cancer ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Hall of Fame second baseman Ryne Sandberg says the prostate cancer he thought had been eliminated by radiation has returned and spread.

(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of ...

Published in Nature Communications, a new study led by the University of Minnesota Medical School and Duke University found ...

By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said Phase 3 of its prostate cancer candidate CAN-2409 showed an upgrade in disease-free survival in intermediate-to-high-risk patients. “We ...

Candel Therapeutics (NASDAQ:CADL) stock rocketed 130% after the company reported positive Phase 3 results for its drug ...

Candel Therapeutics' CAN-2409 shows a 14.5% improvement in prostate cancer survival. Discover why CADL stock stays a "Buy" ...

The latest international Kamal Choudhury news and views from Reuters - one of the world's largest news agencies ...

Candel Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing biological immunotherapies aimed at helping patients fight cancer. The company’s leading product, ...